

Onset of Alzheimer disease in apolipoprotein $\epsilon 4$ carriers is earlier in butyrylcholinesterase K variant carriers

Roger M. Lane, MD¹; Taher Darreh-Shori, PhD²; Candice Junge, PhD¹; Dan Li, PhD¹; Qingqing Yang, PhD¹; Amanda L. Edwards, PhD³; Danielle L. Graham, PhD³; Katrina Moore, PhD¹; Catherine J. Mummery, MD⁴.

Abstract

Background

We wished to examine the impact of the K-variant of *butyrylcholinesterase* (*BCHE-K*) carrier status on age-at-diagnosis of Alzheimer disease (AD) in *APOE4* carriers.

Methods

In 45 patients, aged 50-74 years, with cerebrospinal fluid (CSF) biomarker confirmed mild AD, recruited into a clinical trial (NCT03186989), baseline demographics, disease characteristics, and biomarkers were evaluated by *BCHE-K* and *APOE4* allelic status.

Results

In *APOE4* carriers (N = 33), mean age-at-diagnosis of AD in *BCHE-K* carriers (n = 11) was 6.4 years earlier than in *BCHE-K* noncarriers (n = 22, $P < .001$, ANOVA). In *APOE4* noncarriers (N = 12) there was no similar influence of *BCHE-K*. In *APOE4* carriers with versus those without *BCHE-K*, mean age-at-baseline was over 6 years earlier and accompanied by slightly higher amyloid and tau accumulations. A predominant amyloid, limited tau pathophysiology, and limbic-amnestic phenotype was exemplified

by *APOE4* homozygotes with *BCHE-K*. Multiple regression analyses demonstrated association of amyloid accumulation with *APOE4* carrier status ($P < .029$), larger total brain ventricle volume ($P < .021$), less synaptic injury (Ng, $P < .001$), and less tau (p-tau₁₈₁, $P < .005$). In contrast, tau pathophysiology was associated with more neuroaxonal damage (NfL, $P = .002$), more synaptic injury (Ng, $P < .001$), and higher levels of glial activation (YKL-40, $P = .01$).

Conclusion

Findings concern the genetic architecture of prognosis in early AD, that is fundamental for patients and the design of clinical trials, and that is less well established than the genetics of susceptibility. In mild AD patients aged less than 75 years, the mean age-at-diagnosis of AD in *APOE4* carriers was reduced by over 6 years in *BCHE-K* carriers versus noncarriers. Functional activation of glia may explain much of the effects of *APOE4* and *BCHE-K* on the phenotype of early AD.

Key words

butyrylcholinesterase, cholinergic, glial activation, innate immune, apolipoprotein E, amyloid, tau, sex differences

Background

The cholinergic hypothesis of AD states that selective loss of cholinergic neurons, arising from basal forebrain nuclei, and decreased levels of the neurotransmitter, acetylcholine (ACh), trigger neurodegeneration and cognitive impairment (1). Corticolimbic cholinergic denervation may be evident at early stages of AD (2, 3). The failure of this circuitry is inextricably linked with cognitive deficits in memory, learning, attention, and

processing speed (4). Synaptic release of ACh initiates cholinergic neurotransmission and is rapidly terminated by acetylcholinesterase (AChE) located in the synapse. The availability of ACh in cholinergic synapses is deficient in AD and can be increased with acetylcholinesterase inhibitors (AChE-Is) (5). The cholinergic system produces both rapid focal synaptic signaling and slow diffuse extracellular signaling through alpha 7 nicotinic ACh receptors ($\alpha 7$ -nAChRs), and both act to control glial cell reactivity and functional state (6). Glial cells provide for the homeostasis and neuroprotection of the central nervous system (CNS), and if this functionality is deficient, amyloid pathology can accumulate (7). In contrast, tau tangle pathology is more strongly correlated with glial activation, and microglial and astrocyte activation may better predict the spatiotemporal spread of tau tangles (8, 9).

Apolipoprotein E (APOE) encodes ApoE, the major intercellular lipid carrier in the CNS that is mainly produced by astrocytes, reactive microglia, vascular mural cells, and choroid plexus cells (10, 11). The *APOE4* polymorphism is the major genetic risk factor for sporadic AD (12). In *APOE4* carriers, functional glial responses to clear A β are deficient and favor the accumulation of amyloid pathology (7). Cerebral amyloid accumulation begins earlier in life in *APOE4* carriers than in noncarriers (13, 14).

Butyrylcholinesterase (BuChE), along with AChE, is involved in the enzymatic breakdown of both synaptic and extracellular ACh (15, 16). Astrocytes secrete BuChE and the ACh synthesizing enzyme, choline acetyltransferase (ChAT), to maintain a steady state equilibrium of hydrolysis and synthesis of extracellular ACh (17). In addition to particular populations of neurons in the amygdala and hippocampus (18), BuChE is localized in glia, myelin, and endothelial cells, and continues to increase in concentration with age, especially in the deep cortex and white matter (19). A β , ApoE,

and BuChE interact with each other to influence the catalytic activity of BuChE, and these entities are also prominent constituents of amyloid plaque (20, 21). For example, CSF ApoE protein, in a concentration- and polymorphism-dependent manner, profoundly alters the catalytic functioning and stability of CSF BuChE in patients with mild AD; an interaction that is A β concentration-dependent (20, 22). *BCHE* genotype and CSF BuChE activity are correlated with markers of glial activation in early AD (23, 24). Lower BuChE activity is associated with higher amyloid accumulation in patients with mild AD (24).

The most common single-nucleotide polymorphism (SNP) of *BCHE*, the Kalow-variant (*BCHE-K*; 3q26.1-3q26.2; nucleotide G1615A, codon A539T; rs1803274), is carried by 18-35% of individuals in Western populations (25-28). In *APOE4* carriers, reduced BuChE activity is more marked in *BCHE-K* carriers, with a *BCHE-K* allele dose-dependent reduction in BuChE activity and lowering of glial activation markers (24, 29). The *BCHE-K* and *APOE4* alleles significantly interact to reduce the age-at-onset of AD (30), and to increase the likelihood of progression from mild cognitive impairment (MCI) to AD (27, 31) and from cognitively unimpaired older individuals to early AD (26). Carriers of both *APOE4* and *BCHE-K* alleles in the MCI stage of AD have a limbic-amnestic phenotype and progress most rapidly in the mild stage of AD, where they are the only genotype group with a significant response to AChE-I treatment (27, 31-33).

The primary objective of this cross-sectional analysis of mild AD patients aged less than 75 years was to evaluate *BCHE-K* effects on age-at-onset of AD in *APOE4* carriers. This analysis found evidence for an amyloid-accumulating phenotype in carriers of both *APOE4* and *BCHE-K*, apparently dependent on levels of glial activation,

that mediated an earlier age-at-onset of AD. These findings link amyloid, innate immune, and cholinergic mechanisms in the underlying disease process.

Methods

This trial (NCT03186989) was conducted in accordance with Good Clinical Practice Guidelines of the International Council for Harmonisation, and according to the ethical principles outlined in the Declaration of Helsinki. The complete study (34) was approved by relevant ethics committees. Written informed consent was provided by the participants.

Study eligibility criteria

Eligible study participants were between the ages of 50 and 74; had probable mild AD (amnestic or non-amnestic), defined by a Mini-Mental State Examination score (MMSE) (35) of 20-27, inclusive (representative of mild AD), and either a Clinical Dementia Rating (36) Overall Global Score of 1, or a Global Score of 0.5 with a Memory Score of 1; a CSF pattern of low $A\beta_{1-42}$ (≤ 1200 pg/ml), elevated total-tau (> 200 pg/ml) and p-tau (> 18 pg/ml), and a total-tau to $A\beta_{1-42}$ ratio > 0.28 ; and a diagnosis of probable AD based on National Institute of Aging-Alzheimer Association (NIA-AA) criteria (37).

Assessments

CSF from participants was analyzed for markers of amyloid accumulation (inversely indexed by $A\beta_{42}$), tau pathophysiology (p-tau₁₈₁), neuroaxonal degeneration (NfL), synaptic injury (Ng), glial activation (YKL-40). The CSF analytes and assays are detailed

in Table 1. Of 46 patients entering the study, 45 were characterized for common SNPs of *APOE* (ie, *APOE4*, *APOE3*, and *APOE2*), and *BCHE* rs1803274 (ie, *BCHE-K*).

The study required 3-dimensional (3D) T1-weighted structural magnetic resonance imaging (MRI) scans of the head, volumetric analyses calculated using VivoQuant™, which is comprised of a preprocessing module and a multi-atlas segmentation module, followed by visual inspection and manual editing if needed (38). The mean baseline ventricular volume and hippocampal volume were expressed as a percentage of the total intracranial volume (%TIV).

Table 1. CSF biomarkers of AD pathology, glial activation, inflammation, neuroaxonal damage, and synaptic injury.

CSF analyte	Biology indexed
Aβ₄₂ (β-amyloid 1-42) Elecsys β-amyloid 1-42 CSF performed at Roche Diagnostics, Indianapolis, IN	Parenchymal amyloid accumulation
p-tau₁₈₁ (tau phosphorylated at threonine 181) Elecsys Phospho-Tau (181P) CSF performed at Roche Diagnostics, Indianapolis, IN	Tau tangle pathology
NfL* (neurofilament light chain) Uman, performed at Immunologix, Tampa, FL	Neuroaxonal degeneration
Ng* (neurogranin) Euroimmune, performed at Immunologix, Tampa, FL)	Postsynaptic injury
YKL-40* (chitinase-3-like protein 1) ELLA (Protein Simple), performed at Immunologix, Tampa, FL)	Microglial and astrocyte activation marker (39)

*All CSF samples for NfL, Ng, and YKL-40 were tested using a single batch of reagents.

Statistical analysis

Patient baseline characteristics were summarized according to genotype and sex (Tables 2-4). Quantitative assessments were summarized using descriptive statistics, including number of patients, mean, and standard deviation. Qualitative assessments were summarized using frequency counts and percentages. The exact test was used to examine the Hardy-Weinberg equilibrium (HWE) in the distribution of *APOE* and

BCHE alleles in the study population. All exact tests were performed using the R package “Hardy Weinberg” (40). The HWE *P* value, which measures the strength of evidence against the null hypothesis that the distribution does not follow Hardy-Weinberg equilibrium, was provided. A large *P* value is consistent with the distribution following HWE.

Both analysis of variance (ANOVA) and analysis of covariance (ANCOVA) were used to test whether the mean age-at-diagnosis of AD (primary analysis) or the mean age-at-baseline differed across two or more genotype groups, ie, by *BCHE-K* carrier status in *APOE4* carriers, and in *APOE4* homozygotes and heterozygotes. When the ANCOVA model was applied, the model included *BCHE-K* carrier status and sex as factors, and baseline MMSE total score as covariate. Prior to performing ANOVA and ANCOVA, the normality assumption of residuals was tested using the Kolmogorov-Smirnov test. If significant departures from normality were observed, the Wilcoxon Rank Sum test was applied. Both ANOVA and ANCOVA were applied to test baseline CSF A β_{42} across two or more genotype groups. When ANCOVA was applied, age-at-baseline was included as an additional covariate in the model. If the normality assumption was not satisfied, both ANOVA and ANCOVA model were fitted to the log-transformed data. Box plots were used to visualize data by group.

Relationships between CSF A β_{42} , CSF p-tau $_{181}$, other CSF biomarkers, and brain volumes (in terms of total hippocampal and total brain ventricular volumes as %TIV) were explored in the overall population and in each genotype group in a simple linear correlation analysis with a Pearson correlation coefficient. The squared Pearson correlation coefficient (R^2) and *P* value were provided in the correlation analysis and interpreted by descriptors to indicate the strength of the relationship. Correlation

coefficients with a magnitude of $0.81 < R^2 < 1$ indicate variables were very highly/strongly correlated; $0.49 < R^2 < 0.81$ indicates highly/strongly correlated; $0.25 < R^2 < 0.49$ indicates moderately correlated; $0.09 < R^2 < 0.25$ indicates a low/weak correlation; and $R^2 < 0.09$ indicates negligible correlation. Scatterplots with a simple linear regression line were produced to depict the relationships between two quantitative variables.

Multiple regression analysis was also utilized to assess the functional relationships between the biomarker of interest and amyloid and tau pathophysiology. A multiple regression model was applied with CSF $A\beta_{42}$ and CSF p-tau₁₈₁ as the response variables, and *APOE4*, *BCHE-K*, age-at-baseline, sex, baseline MMSE total score, and the biomarker of interest (ie, CSF p-tau₁₈₁ or $A\beta_{42}$, NfL, Ng, YKL-40; total hippocampal volume, total brain ventricular volume) as independent variables. This determined the strength of association of CSF $A\beta_{42}$ or CSF p-tau with parameters of interest, in conjunction with the other independent variables included in the model.

Results

The study was conducted at 12 centers in Canada, Finland, Germany, the Netherlands, Sweden, and the UK between August 2017 and February 2020. 102 patients were assessed for eligibility. Of these, 56 were excluded, and one enrolled participant did not provide genetic test results. The study sample comprised 45 participants with a mean age of 65.8 years and a mean baseline MMSE total score of 23.6.

The *APOE4* allele was carried by 73% (33) of participants; 22% (10) homozygotes and 51% (23) heterozygotes (Table 2). The *BCHE-K* allele was carried by 36% (16) of participants; 7% (3) homozygotes and 29% (13) heterozygotes (Table S1). Of the 16


BCHE-K carriers, 69% (11) were *APOE4* carriers (Table 3). All non-*APOE4* alleles were *APOE3*, except for one participant with an *APOE2/3* genotype, who also carried one *BCHE-K* allele. Both the distribution of *APOE* genotypes (HWE exact P value = 1) and *BCHE* genotypes (HWE exact P value = .376) were consistent with Hardy-Weinberg equilibrium.

Age-at-diagnosis of AD in *APOE4* carriers was reduced in carriers of *BCHE-K* alleles

There were no significant *APOE4* carrier or allele frequency-associated differences on the participants' age-at-diagnosis of AD or on their age-at-baseline of study (Table 2). *APOE4* homozygotes ($n = 10$) had a mean age-at-diagnosis of AD of 64.2 years versus heterozygotes ($n = 23$) of 65.2 years, versus noncarriers ($n = 12$) of 63.3 years. In contrast, *BCHE-K* homozygotes ($n = 3$) had a lower mean age-at-diagnosis of AD of 59.4 years versus heterozygotes ($n = 13$) of 62.2 years, versus noncarriers ($n = 29$) of 66.0 years ($P = .048$, ANOVA) (Table S1).

In the primary analysis of this investigation, amongst *APOE4* carriers, *BCHE-K* carriers ($n=11$) versus noncarriers ($n=22$) were associated with differences in mean age-at-diagnosis of AD of 6.4 years (60.6 versus 67.0; $P < .001$, ANOVA; $P = .001$, ANCOVA) (Figure 1A; Table 3), and mean age-at-baseline of study of 6.2 years (62.1 versus 68.3; $P = .001$, ANOVA; $P = .002$, ANCOVA) (Figure 1C). The difference in mean age-at-diagnosis of AD in *BCHE-K* carriers versus noncarriers was similar in *APOE4* heterozygotes at 6.7 years (60.5 versus 67.3 years) and homozygotes at 5.7 years (60.8 versus 66.4 years) ($P = .013$, ANOVA; $P = .019$, ANCOVA) (Figure 1B). Significant differences of a similar magnitude were also seen in age-at-baseline of study (Figure 1D).

Figure 1. Age-at-diagnosis of AD and age-at-baseline by *BCHE-K* carrier status in *APOE4* carriers, homozygotes, and heterozygotes



Box interior: mean = Δ , median = horizontal line

A. Age-at-diagnosis of AD in *APOE4* carriers by *BCHE-K* carrier status

B. Age-at-diagnosis of AD in *APOE4* homozygotes and heterozygotes by *BCHE-K* carrier status

C. Age-at-baseline of study in *APOE4* carriers by *BCHE-K* carrier status

D. Age-at-baseline of study in *APOE4* homozygotes and heterozygotes by *BCHE-K* carrier status

* $P < .001$, ANOVA; $P = .001$, ANCOVA with *BCHE-K* carrier status and sex as factors and baseline MMSE total score as covariate for mean age-at-diagnosis of AD.

** $P = .013$, ANOVA; $P = .019$, ANCOVA with *APOE4* homozygotes and heterozygotes by *BCHE-K* carrier status and sex as factors and baseline MMSE total score as covariate for mean age-at-diagnosis of AD.

† $P = .001$, ANOVA; $P = .002$, ANCOVA with *BCHE-K* carrier status and sex as factors and baseline MMSE total score as covariate for mean age-at-study-baseline.

†† $P = .015$, ANOVA; $P = .025$, ANCOVA with *APOE4* homozygotes and heterozygotes by *BCHE-K* carrier status and sex as factors and baseline MMSE total score as covariate for mean age-at-study-baseline.

In *APOE4* noncarriers (N = 12), the mean age-at-diagnosis and age-at-baseline of the study were similar between *BCHE-K* carriers (n = 5) at 63.9 and 64.8 years, respectively, and noncarriers (n = 7) at 62.8 and 64.4 years, respectively (Table 3).

Table 2. Mild AD phenotype across genotype groups defined by *APOE4* allele frequency and for *APOE4* homozygotes by the presence of *BCHE-K* alleles.

		2 <i>APOE4</i> & <i>BCHE-K</i>			No <i>APOE4</i>	1 or 2 <i>APOE4</i>
	Mean value for variable (SD)	(N = 4)	2 <i>APOE4</i> (N = 10)	1 <i>APOE4</i> (N = 23)	(N = 12)	(N = 33)
Sex	Female	75%	60%	52%	33%	55%
Onset of AD	Age-at-diagnosis (yrs)	60.8 (4.4)	64.2 (5.4)	65.2 (5.8)	63.3 (7.4)	64.9 (5.6)
	Time since AD diagnosis at baseline (yrs)	1.2 (1.2)	1.2* (1.2)	1.4† (1.3)	1.3† (1.5)	1.4 (1.2)
Neuroimaging	Hippocampal vol., % of ICV	0.26 (0.05)	0.24* (0.04)	0.25* (0.04)	0.28† (0.03)	0.25 (0.04)
	Ventricular vol., % of ICV	1.8 (0.73)	1.8† (0.53)	3.3* (1.32)	2.7* (1.08)	2.8 (1.31)
CSF markers	Aβ ₄₂ , pg/mL	554 (111)	581* (110)	700† (188)	799† (180)	664 (175)
	p-tau ₁₈₁ , pg/mL	34.0 (11.8)	35.2† (9.3)	41.1* (15.2)	41.3* (13.8)	39.3 (13.8)
	NfL, pg/mL	1003 (265)	1039† (319)	1383* (438)	1399* (296)	1279 (432)
	Ng, pg/mL	493 (188)	482† (120)	546* (271)	526* (235)	527 (235)
	YKL-40, ng/mL	190 (86.0)	202† (63.8)	267* (114.9)	318* (161.9)	247 (105.6)
Cognition	MMSE Total (0-30)	24.3 (2.5)	24.4† (2.1)	23.3* (2.3)	23.7* (2.2)	23.6 (2.3)
	MMSE Memory (0-6)	4.0 (1.4)	4.1* (1.0)	4.0* (1.1)	4.6† (1.2)	4.1 (1.1)
	MMSE Visual Construction (0-1)	0.8 (0.5)	0.8† (0.4)	0.7† (0.5)	0.5* (0.5)	0.7 (0.5)
	RBANS Total (40-160)	72.8 (8.3)	73.4† (10.5)	64.0* (11.2)	68.5* (12.3)	66.8 (11.7)
	RBANS Delayed Memory (40-154)	56.0 (19.3)	52.8* (12.5)	48.0* (7.4)	66.3† (22.5)	49.5 (9.3)
	RBANS Visuospatial/Constructional (40-154)	101.8 (28.8)	100.8† (20.0)	81.1* (19.8)	79.9* (21.7)	87.1 (21.6)

Across only the *APOE4* allele-frequency groups: * Numerically more pathology or more clinical impairment; † Numerically less pathology or less clinical impairment.

ICV, intracranial volume; MMSE, Mini-Mental Status Examination; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SD, standard deviation.

In *APOE4* carriers with *BCHE-K*, younger mean age-at-baseline was accompanied by slightly higher amyloid and tau accumulations (Table 3)

Across genotype groups defined by *APOE4* and *BCHE-K* carrier status the proportion of female participants fell as the burden of *APOE4* and *BCHE-K* alleles diminished (Table 3). Carriers of both alleles had the earliest age-at-diagnosis, generally greater memory deficits, and the most amyloid accumulation. *APOE4* carriers with *BCHE-K* had slightly higher amyloid and tau accumulations than *APOE4* carriers without *BCHE-K*, despite a mean age-at-baseline that was 6.2 years earlier. In *APOE4* carriers, neurodegeneration and glial activation were similar between carriers and noncarriers of *BCHE-K* (Table 3). On the other hand, noncarriers of both *APOE4* and *BCHE-K* had the least amyloid pathology and multidomain cognitive deficits, with relatively less memory impairment. Individuals in these contrasting groups, defined by the presence or absence of both *APOE4* and *BCHE-K* alleles, had similar levels of tau and neurodegenerative pathology (Table 3).

Table 3. Mild AD phenotype across genotype groups defined by *APOE4* and *BCHE-K* carrier status.

	Mean value for variable (SD)	<i>E4</i> & <i>K</i> (N = 11)	<i>E4</i> & <i>No-K</i> (N = 22)	<i>No-E4</i> & <i>K</i> (N = 5)	<i>No-E4</i> & <i>No-K</i> (N = 7)
Sex	Female	64%	50%	40%	29%
Onset of AD	Age-at-AD diagnosis (yrs)	60.6* (6.1)	67.0† (4.0)	63.9 (7.6)	62.8 (7.8)
	Age-at-baseline (yrs)	62.1* (5.9)	68.3† (4.0)	64.8 (7.3)	64.4 (6.6)
	Time since AD diagnosis at baseline (yrs)	1.5† (1.3)	1.3* (1.2)	0.9* (0.7)	1.6† (1.9)
Neuroimaging	Hippocampal vol., % of ICV	0.26* (0.05)	0.24* (0.03)	0.28† (0.02)	0.28† (0.03)
	Ventricular vol., % of ICV	2.9* (1.54)	2.8† (1.23)	2.3† (0.97)	2.9* (1.15)
CSF markers	Aβ ₄₂ , pg/mL	641* (139)	676* (193)	755† (195)	831† (176)
	p-tau ₁₈₁ , pg/mL	40.4* (12.2)	38.7† (14.8)	42.5* (15.8)	40.4* (13.5)
	NfL, pg/mL	1392* (498)	1222† (395)	1316† (160)	1458* (366)
	Ng, pg/mL	568* (188)	506† (257)	540* (245)	515† (247)
	YKL-40, ng/mL	247† (143.3)	247† (85.0)	351* (164.5)	293* (168.5)
Cognition	MMSE Total (0-30)	23.8† (2.5)	23.5* (2.3)	23.4* (2.4)	23.9† (2.3)
	MMSE Memory (0-6)	3.9* (1.0)	4.1* (1.1)	4.2* (1.3)	4.9† (1.2)
	MMSE Visual Construction (0-1)	0.7† (0.5)	0.7† (0.5)	0.8† (0.4)	0.3* (0.5)
	RBANS Total (40-160)	65.5* (10.5)	67.5† (12.4)	72.0† (13.4)	66.0* (11.8)
	RBANS Delayed Memory (40-154)	52.7* (13.7)	47.8* (5.9)	69.0† (26.2)	64.3† (21.5)
	RBANS Visuospatial/Constructional (40-154)	90.4† (25.6)	85.4† (19.8)	79.4* (21.1)	80.3* (23.9)

* Numerically more pathology or more clinical impairment; † Numerically less pathology or less clinical impairment; ICV, intracranial volume; MMSE, Mini-Mental Status Examination; Repeatable Battery for the Assessment of Neuropsychological Status; SD, standard deviation.


Higher *APOE4* allele frequency associates with amyloid pathology and the limbic-amnesic phenotype (Table 2)

Female participants exhibited a higher *APOE4* allele frequency than male participants.

In *APOE4* carriers, there was a more temporo-limbic (hippocampal atrophy > ventricular expansion) and amnesic (memory > visuospatial impairment) phenotype

relative to *APOE4* noncarriers (Table 2). *APOE4* carriers relative to noncarriers had higher levels of amyloid pathology (inversely indexed by the CSF $A\beta_{42}$ = 664 versus 799 pg/mL, respectively; $P = .028$ ANOVA, $P = .028$ ANCOVA) (Table 2). *APOE4* homozygotes had the highest levels of amyloid pathology (CSF $A\beta_{42}$ = 581 pg/mL) and the lowest levels of tau pathophysiology (CSF p-tau₁₈₁ = 35.2 pg/mL), neuroaxonal damage (NfL), and synaptic injury (Ng). Glial activation (YKL-40) showed apparent *APOE4* allele frequency-dependent decreases to the lowest levels in homozygotes. Amyloid pathology was further increased in *APOE4* homozygotes with *BCHE-K* (CSF $A\beta_{42}$ = 554 pg/mL), with further reductions of tau (CSF p-tau₁₈₁ = 34.0 pg/mL), neurodegenerative pathology, and glial activation (Table 2).

Figure 2. Correlations of CSF $A\beta_{42}$ versus CSF p-tau₁₈₁ in the overall population and in *APOE4* and *BCHE-K* subgroups




Simple linear correlation analyses: R square and P value were obtained by fitting a simple linear regression model.

More amyloid pathology associated with less tau pathophysiology especially in carriers of both *APOE4* and *BCHE-K* (Figure 2)

Multiple regression analyses indicated that associations with amyloid pathology (inversely indexed by CSF $A\beta_{42}$) included *APOE4* carrier status ($P < .029$), larger total brain ventricle volume ($P < .021$), less synaptic injury (Ng, $P < .001$), less tau (p-tau₁₈₁, $P = .005$), and showed a trend for an association with less glial activation ($P = .097$). In

simple linear correlation analyses in the overall population, amyloid pathology showed weak to moderate inverse correlations with tau pathophysiology, synaptic injury, and glial activation (Figures 2, 3B, and 3C). In carriers of both *APOE4* and *BCHE-K*, inverse correlations of amyloid with both synaptic injury and tau pathophysiology strengthened to moderate and weak inverse correlation with glial activation persisted but was not statistically significant (Figures 2, 3B, and 3C). In *APOE4* carriers without *BCHE-K*, inverse correlations of amyloid with tau pathophysiology were weak, and with synaptic injury and glial activation were moderate (Figures 2 and 3C).

Figure 3. Correlations of neurodegenerative and glial activation markers with CSF A β_{42} and CSF p-tau $_{181}$ in the overall study population and in genotype groups



A. CSF neurofilament light chain (NfL) (higher levels index more neuroaxonal injury)

B. CSF neurogranin (Ng) (higher levels index more synaptic injury)

C. CSF YKL-40 (higher levels index more glial activation)

Simple linear correlation analyses: R square and P value were obtained by fitting a simple linear regression model.

Only those analytes associated with either CSF A β_{42} or CSF p-tau $_{181}$ in multiple regression analyses are shown.

Tau pathophysiology associated with synaptic injury and glial activation, especially in noncarriers of both *APOE4* and *BCHE-K*, and with neuroaxonal degeneration, especially in *APOE4* carriers without *BCHE-K* (Figure 3)

Multiple regression analyses indicated associations with tau pathophysiology (p-tau₁₈₁) with higher CSF levels of NfL ($P = .002$), Ng ($P < .001$), and YKL-40 ($P = .01$). Thus, more tau pathophysiology associated with neuroaxonal and synaptic degeneration, and glial activation. In simple linear regressions in the overall population, tau pathophysiology was moderately correlated with neuroaxonal damage, highly correlated with synaptic injury, and weakly correlated with glial activation (Figures 3A-C). Simple linear regressions showed correlations of tau pathophysiology with synaptic injury that was moderate in *APOE4* carriers without *BCHE-K*, strong in carriers of both *APOE4* and *BCHE-K*, and very strong in *APOE4* non-carrier subgroups (Figure 3B). Simple linear regression showed tau pathophysiology had a moderate correlation with the neuroaxonal degeneration in the overall group, and this strengthened to highly correlated in *APOE4* carriers without *BCHE-K* (Figure 3A). In simple linear regressions, correlation of glial activation with tau pathophysiology was weak in the overall population, weak in *APOE4* carriers without *BCHE-K*, and very strong in noncarriers of both *APOE4* and *BCHE-K* (Figure 3C). YKL-40 is proposed as a marker of tau pathology (41).

Discussion

In this sample of clinically and pathologically characterized mild AD patients aged less than 75 years, *APOE4* carriers with *BCHE-K* had a mean age-at-diagnosis of AD 6.4 years earlier than in *APOE4* carriers without *BCHE-K* (Figure 1A). In *APOE4* carriers, slightly higher accumulations of amyloid and tau pathophysiology were present in

BCHE-K carriers over 6 years earlier than in *BCHE-K* noncarriers (Table 3). The magnitude of this modifier effect may be due to a population age range in which the effects of *APOE4* on the AD phenotype are maximal and most modifiable. *APOE4* allele frequency-dependent effects on the risk-of-onset of AD are highest in the seventh decade, wane over 70 years of age, and are particularly reduced after 80 years of age (42, 43). The restricted age range for entry into the current study may also have been at least partly responsible for the lack of any significant *APOE4* allele frequency-dependent effects on age-at-diagnosis of AD or age-at-baseline (Table 2).


Amyloid pathology may accumulate at an earlier age in *APOE4* carriers with *BCHE-K* alleles

APOE4/E4 individuals start accumulating amyloid at an earlier age, followed by *APOE3/E4*, *APOE2/E4*, *APOE3/E3*, and *APOE2/E3* (13). The age of symptom onset may strongly correlate with the age at which an individual reaches a tipping point in fibrillar A β accumulation (44). In the current study, amyloid accumulation reached higher levels in genotype groups with lower levels of glial activation and an inverse correlation was observed between amyloid pathology and glial activation (Table 2; Figure 3C). Levels of amyloid pathology across genotype subgroups are compatible with *APOE4* allele frequency-dependent accumulation beginning at an earlier age with the earliest start in *APOE4* carriers with *BCHE-K* alleles, particularly in *APOE4* homozygotes with *BCHE-K* (Table 2).

An age- and genotype-dependent phenotypic extreme of limbic-amnestic and amyloid-predominant mild AD is associated with low levels of glial activation (Figures 3 and 4; Table 2)

Optimally, glial activation may balance needs to attenuate amyloid accumulation and limit the spread of tau pathology (45, 46). This is an important determinant of the pathology mix and clinical features of early AD, including the age-of-onset of AD, and it links amyloid and tau pathology, cholinergic signaling, and glial activation (33).

Figure 4. Amyloid pathology facilitating phenotype of mild AD exemplified by *APOE4* homozygotes with *BCHE-K* aged < 75 years



In preclinical and prodromal AD, lower BuChE activity, especially in *APOE4* homozygote *BCHE-K* carriers below 75 years of age, results in higher extracellular ACh and increased signaling through nAChR on glial cells (1). “Functionally underactive” glia with decreased phagocytic function and homeostatic responsiveness (2), impair Aβ clearance and induce earlier and greater amyloid accumulation (3). In prodromal and mild AD, limbic cholinergic denervation due to ApoE4-, Aβ- and tau-mediated damage to basal forebrain cholinergic neurons, removes the cholinergic “brake” on glia to increase glial activation, tau pathology and neurodegeneration in the MTL (4), but the spread of this pathology outside of the MTL is initially limited until cholinergic denervation has progressed to include other neocortical areas (5). Thus, high levels of amyloid accumulation develop at a younger age, and basal forebrain cholinergic denervation of MTL structures results in hippocampal atrophy and a rapidly progressing limbic-amnestic presentation in mild AD with good response to AChE-Is (6). The progression of corticolimbic cholinergic denervation to neocortical areas beyond the MTL results in the spread of glial activation, tau pathology, and neurodegeneration.

At one end of the age- and genotype- and disease stage-dependent spectrum of early AD is the limbic-amnestic and amyloid accumulation-predominant phenotype, exemplified *APOE4* homozygotes with *BCHE-K* alleles aged less than 75 years (Table 2). In *APOE4* carriers with *BCHE-K*, greater accumulation of A β pathology at younger ages is likely due to greater deficits in glial-mediated clearance mechanisms (7, 47) (Figures 3C and 4). These functionally underactive glia may produce proinflammatory cytokines and be classified as “inflammatory,” but their endolysosomal and phagocytic functions may be greatly reduced (48). Putatively lower BuChE activity in *BCHE-K* carriers with *APOE4* alleles results in higher extracellular ACh, further reduces the phagocytic function and responsiveness of glial cells, and further impairs A β clearance. While excessive cholinergic signaling encourages high levels of amyloid accumulation, the spread and accumulation of tau pathology is kept in check (Figures 2 and 4). However, in early AD, *APOE4* is associated with rapidly increasing tau pathology as the combination of ApoE4 and A β pathology induces sufficient degeneration of basal forebrain corticolimbic cholinergic neurons to release the cholinergic “brake” on glial activation in the medial temporal lobe (MTL) and eventually also in other cortical regions (Figure 4). Cholinergic denervation and tau pathology accumulating in the MTL results in a rapidly progressing limbic-amnestic presentation with response to AChE-I that is apparent in the mild stage of AD (32, 33). The focal MTL/limbic denervation is indexed by a more limbic-amnestic presentation (memory > visuospatial impairment, and hippocampal atrophy > ventricular expansion) (Tables 2 and 3).

Both A β and ApoE modulate the cholinergic system

The cholinergic system acts to control glial reactivity and function through $\alpha 7$ -nAChRs via rapid focal synaptic signaling and slow diffuse extracellular signaling (6). ApoE forms soluble and highly stable complexes with cholinesterase enzymes and A β , that can oscillate between slow and ultrafast ACh hydrolysis, depending on A β availability (29). Reduced cholinesterase activity and lowering of glial activation markers is seen in *APOE4* carriers, particularly in individuals with polymorphic variants of genes encoding cholinesterase enzymes with lower activity, such as *BCHE-K* (24, 29). In addition, lower cholesterol delivery by ApoE4 to the long and extensively arborized axons of the metabolically taxed cholinergic neurons requires them to expend energy on cholesterol synthesis and to consume acetyl coenzyme A (acetyl-CoA) (49). Acetyl-CoA is an essential substrate for the synthesis of both ACh and lipids essential for myelin formation and maintenance of cellular membranes (50). The ascending white matter projections of the basal forebrain cholinergic system may be particularly vulnerable to the combination of A β pathology and ApoE4 (51-53).

In a concentration- and aggregation-dependent manner, A β targets cholinergic synapses, signals through $\alpha 7$ -nAChRs, and also influences the extracellular fluid equilibrium between breakdown and synthesis of ACh via effects on ACh-hydrolyzing capacity of cholinesterase (22) and choline acetyltransferase (ChAT) activity (54). In both aging and AD, the intraneuronal accumulation of oligomeric assemblies of A β_{42} is a relatively selective trait of basal forebrain cholinergic neurons (55, 56), and endocytic internalization of A β -nAChR complexes may underlie intracellular accumulation of A β_{42} and its neurotoxic consequences, such as tau phosphorylation (57). In AD, $\alpha 7$ -nAChR expression on astrocytes is positively correlated with neuritic plaque burden (58). In an

amyloid mouse model, loss of $\alpha 7$ -nAChRs reduced $A\beta_{42}$ plaque load, but increased levels of soluble $A\beta_{42}$ oligomers and accelerated memory decline (59). Thus, $A\beta$ and ApoE have physiological and disease roles in the tuning of cholinergic activity and in the vulnerability of the basal forebrain cholinergic system to degeneration, and these actions influence the functional status of cholinergic neuronal and nonexcitable cells (17).

Hypofunctional glial-mediated clearance of $A\beta$ likely underlies the “amyloid accumulating” phenotype exemplified by carriers of *APOE4* and *BCHE-K* aged < 75 years. A balanced activation of glia may be needed to stimulate $A\beta$ clearance and avoid “hypofunctional” glia promoting amyloid accumulation versus “hyperactivated” glia that facilitate the dissemination of tau (45, 46, 60). In amyloid mouse models, inhibition of reactive astrogliosis increases $A\beta_{42}$ plaque burden (61), whereas shifting microglia to an interferon-responsive state boosts ApoE expression, phagocytosis, containment of plaques, and lessens damage to nearby neurons and synapses (62). However, further shifting of microglia to an overactivated state may increase synaptic engulfment and accelerate the dissemination of tau pathology (63). Mouse models indicate that ApoE controls glial activation, with ApoE4 locking microglia in a homeostatic state with failure to clear neurodegenerative pathology (7, 47). Glia in *APOE4* mice demonstrate a significant decrease in phagocytic capacity (64). Microglial and astrocyte coverage of plaques is likely protective for surrounding neurons, and ApoE4 is associated with decreased coverage and more neuronal dystrophy (65-67).

BCHE-K carriers, who have lower levels of glial activation markers and higher levels of proinflammatory cytokines (24, 68), may exhibit deficient glial responses to neurodegeneration. Rapid and appropriately tuned changes in the catalytic activity of

BuChE, and necessary adaptive changes in cholinceptive nonexcitable cells may be more difficult to achieve with BuChE-K, particularly in *APOE4* carriers. Carriers of *APOE4* and *BCHE-K* may have more senescent microglia that are associated with blocked endolysosomal processing, impaired phagocytosis, and with acceleration of $A\beta_{42}$ pathology (69). YKL-40 is a context-dependent modulator of glial phagocytic activity in both mice and humans (70). In the current study, *APOE4* noncarriers had higher mean levels of CSF YKL-40, at 318 ng/mL, relative to *APOE4* carriers at 247 ng/mL (Table 2). Mean levels were further reduced in *APOE4* homozygotes at 202 ng/mL and in *APOE4* homozygotes with *BCHE-K* alleles at 190 ng/mL (Table 2). This likely explains the inverse correlation between amyloid pathology and YKL-40 and synaptic injury seen in simple linear regression analyses overall and more specifically in *APOE4* carriers (Figure 3B and 3C). In addition, a weak correlation between YKL-40 and synaptic injury overall was evident in *BCHE-K* non-carriers (Figure S1). The correlation persisted as weak in *APOE4* carriers without *BCHE-K* and strengthened to high in non-carriers of both *APOE4* and *BCHE-K*.

Increases in functional glial activation with age might explain why *APOE4*-associated risk for AD reduces over the age range of 70-80 years, and why progression to dementia in prodromal AD carriers of both *APOE4* and *BCHE-K* is at least 2-fold higher in those aged below 75 years relative to older patients (33). In a longitudinal study of prodromal AD, progression to AD over 3-4 years in *APOE4* and *BCHE-K* carriers was 39% in participants aged less than 75 years and decreased to 18% in those aged 75 years or more (33). This was contrary to findings in the overall study, where progression to AD was greater in older participants (29%), relative to those aged less than 75 years (13%). Younger *APOE4* carriers have accelerated progression of

hippocampal atrophy in prodromal and early stage AD, but in individuals more advanced in age or in progression of disease, any influence of *APOE4* on hippocampal atrophy is lost (71). Moreover, global cerebral atrophy in AD patients with a mean age of 70 years was reduced in an *APOE4* allele frequency-dependent manner (72), whereas in older patients, with a mean age of 80 years, atrophy was no different by genotype (71, 73).

The “amyloid accumulating and initially tau spread limiting” phenotype supports the amyloid cascade hypothesis

Carriers of *APOE4* and *BCHE-K* with prodromal AD, in addition to progression rates to AD that inversely correlated with age, had the greatest hippocampal atrophy and declines in short- and long-term retrieval from verbal memory and overall cognitive impairment (27, 33). Likewise, in the current study of mild AD patients, *APOE4* carriers relative to noncarriers had greater memory deficits, hippocampal atrophy, and amyloid accumulation, and these findings in *APOE4* carriers occurred over 6 years earlier in *BCHE-K* carriers compared to noncarriers (Figure 1C, Table 3). The amyloid cascade hypothesis of AD implies that reaching the threshold for parenchymal amyloid positivity at an earlier age should drive secondary effector tau pathology, with an earlier age-at-onset of AD (74). Support for this hypothesis comes from slower progression of tau tangle accumulation and cognitive decline following antibody-induced removal of amyloid plaque below key threshold levels in patients with early symptomatic AD (75, 76). However, in the current study, correlations of amyloid pathology with tau pathophysiology in *APOE4* carriers were negative, particularly in carriers of both *APOE4* and *BCHE-K* (Figure 2). Across groups defined by *APOE4* allele frequency, *APOE4* homozygotes had the highest amyloid pathology and lowest tau and

neurodegenerative pathology (Table 2). Amyloid pathology was further increased in *APOE4* homozygotes with *BCHE-K*, with further reduction of tau and neurodegenerative pathology (Table 2).

The inverse correlations of amyloid pathology with tau pathophysiology and synaptic injury may be a consequence of tau and neurodegenerative pathology localized to the MTL (which includes the entorhinal cortex, amygdala, and hippocampus). This MTL tau and neurodegenerative pathology may be responsible for transitioning *APOE4* and *BCHE-K* carriers into AD at an earlier age with less global tau and neurodegenerative pathology (Table 3; Figure 4) (77, 78). Such neuroanatomical distinctions are not discernible on CSF indices that summarize pathology changes across the brain. Spatial resolution requires tau tangle-ligand positron-emission tomography (tau-PET) neuroimaging. In the presence of global amyloid pathology in *APOE4* carriers, tau-PET indicates that tau pathology is more severe with a focal MTL distribution (78, 79). Furthermore, younger age is associated with PET-tau signal in the MTL in early AD *APOE4* carriers but not in *APOE4* noncarriers (78). Across the aging and AD spectrum, *APOE4* carriers present increased microglial activation relative to noncarriers in early Braak stage regions within the MTL and this microglial activation mediates A β -independent effects of *APOE4* on tau accumulation that are further associated with neurodegeneration and clinical impairment (80).

Degeneration of basal forebrain cholinergic neurons, that project to the MTL and other cortical structures, precedes and predicts longitudinal entorhinal/MTL degeneration (81, 82) and preclinical *APOE4* carriers exhibit the greatest loss of basal forebrain volume (83). The ascending neuronal projections of the basal forebrain

cholinergic system may be particularly vulnerable to the combination of ApoE4-mediated glial hypofunction, high levels of A β , and tau pathologies (51-53). The impact of focal basal forebrain pathology is magnified as it causes widespread presynaptic cholinergic corticolimbic denervation. Both amyloid and tau pathologies may be required for substantial impairment of cholinergic synaptic plasticity and memory, and continuous destruction of the projecting branches of the cholinergic nuclei in the basal forebrain (84, 85).

Implications for future clinical research and development of therapeutics

Findings in the current study, if confirmed, could have implications for the conceptualization of Alzheimer pathological cascades, therapeutic targets, and the application of existing and future treatments. The genetic architecture of prognosis in AD, that is fundamental for patients and the design of clinical trials, is less well established than the genetics of susceptibility. *BCHE-K* may join *APOE4* allele frequency, age, and sex as a foundational component of predictive modelling of early AD phenotypes (86, 87). Moreover, the cholinergic hypothesis appears seamlessly interlinked with the amyloid cascade hypothesis. *APOE* and *BCHE* genotypes appear to exert critical influence on the functional activation of glia as indexed by the microglial and astrocyte activation marker, YKL-40, in the CSF. Levels of extracellular cholinergic signaling to cholinergic cells, including glia, depend on the enzymatic activity of BuChE, that relies on BuChE levels and polymorphic variation, ApoE levels and polymorphic variation, and soluble A β levels. The health of cholinergic neurotransmission and extracellular signaling systems may be crucial to healthy brain aging (88).

The quantitative removal of amyloid pathology with anti-amyloid antibodies is dependent on Fc receptor-mediated phagocytosis and clearance of A β (75, 76). Response to this targeted immune activating therapeutic approach may vary depending on the individual's predominant microglial state. While some beneficial effects might be due to antibody-mediated stimulation of glia with improved performance of homeostatic functions (89), stimulating the clearance of A β prior to substantial levels of corticolimbic cholinergic denervation and spreading MTL tau pathology may produce the best outcomes in *APOE4* carriers below the age of 75 years, but this may require intervention in asymptomatic individuals. In addition, longer treatment durations may be necessary in substantial amyloid accumulators, such as *APOE4* homozygotes with *BCHE-K* alleles, to get below the amyloid threshold to prevent or slow further corticolimbic cholinergic denervation and tau pathology.

While retuning of innate immune responses may be required to harness protective and beneficial effects and to attenuate negative effects, the required changes will differ across a genotype, age, and disease stage continuum. Tuning in the wrong direction will simply make matters worse. Considerations may be further complicated by the nuances and complexity of glial cell phenotypes across different brain regions, between adjacent glia, and in different disease contexts (90). The challenge in the development of potential amyloid pathology reducing therapeutics may not lie in simply upregulating the activation state of glia.

Limitations

Strengths of the study include the well characterized sample of older individuals aged less than 75 years with CSF biomarkers and standardized clinical assessments in expert

clinical settings. The limitations of this cross-sectional investigation include its small size and the possibly unrepresentative nature of those enrolled in an interventional clinical trial. Evaluation of the age-at-diagnosis of AD might have benefited from the use of standardized prospective assessments of diagnosis and of onset-age across study sites. Nonetheless, similar genotype group relationships were also demonstrated on the age-at-baseline of study. The findings in the current study appear age-dependent and should not be extrapolated to mild AD patients aged over 75 years. Prospective longitudinal assessment in larger samples is necessary to better evaluate phenotypic evolution along the AD continuum and to confirm and develop these findings.

Although many CSF biomarkers, neuroimaging markers, and clinical assessments were performed, an even more extensive mapping of inflammatory mediators, complement and myelin markers, and CSF ApoE and BChE levels and activity may have been illuminating. The primary biomarker used in this study to index tau pathophysiology (CSF p-tau₁₈₁) may reflect a mix of amyloid and tau pathological changes in the brain (91), and is therefore not a “pure” marker of tau tangle load in the brain. Glia were simplistically ascribed net activated or hypofunctional phenotypes, and as facilitating or limiting amyloid accumulation or tau spread. The association of levels of the astrocyte and microglial activation marker, CSF YKL-40, with transcriptional, morphological, and functional states of glia are not clear, and large multiomic datasets and machine learning may be required to elucidate them.

Although this investigation in study participants of largely European ancestry focused on the influence of specific SNPs in the *APOE* and *BCHE* genes, heterogeneity in the genetic neighborhood of these genes and local *APOE* and *BCHE* haplotypes may be of importance (92). In addition, other than the *K*-variant, the many other genetic

variants of *BCHE* were not assessed in the current study (93), and some of those have been shown to unequivocally impact the amyloid cascade (94). Lastly, discerning clinical phenotypes in different genotype and sex subgroups on a variable background of ChE-I therapy and medications with potential anticholinergic properties may be problematic, as such therapy can influence phenotypic expression. For example, *APOE4* carriers—especially those with concomitant *BCHE-K* alleles—are particularly responsive to AChE-I treatment in the mild stage of AD, and the magnitude of attention, processing speed, and amnesic deficits in these individuals may have been partly obscured (32).

Conclusion

Below the age of 75 years, AD may be more monocausal, without substantial contributions from other age-related pathologies, and the influence of modifying genetic variation on the phenotype of mild AD may be more apparent. In *APOE4* carriers, the presence versus the absence of *BCHE-K* alleles associated with a significantly earlier mean age-at-diagnosis of AD of 6.4 years, a more limbic-amnesic phenotype, and similar accumulations of amyloid and tau pathology but more than 6 years earlier. Thus, in *APOE4* carriers below the age of 75 years, a major contribution to earlier age-at-diagnosis of AD may be concomitant *BCHE-K* alleles. In *APOE4* carriers, *BCHE-K* further reduces the functional activation of glia by increasing cholinergic synaptic signaling from basal forebrain corticolimbic cholinergic neuronal projections and extracellular cholinergic signaling through cell surface $\alpha 7$ -nAChRs. The further lowering of glial activation results in earlier amyloid pathology accumulation that, in combination with ApoE4, is particularly damaging to basal forebrain corticolimbic cholinergic neurons. The spread of tau and synaptic pathology from the MTL to other cortical areas

parallels the denervation of corticolimbic cholinergic projections, removal of the cholinergic “brake” on cortical glial activation, and the onset and progression of symptoms. The functional activation of glia, the amyloid cascade hypothesis and the cholinergic hypothesis of AD are interwoven. In this mild AD population, the concept has the potential to explain much of the phenotypic heterogeneity, and to enable more appropriate use of existing, emerging, and future therapies. Confirmation of these post hoc findings in larger, prospective, and longitudinal studies is required.

Supplementary Material

Raw data (including Mean [SD, SEM], Median [P25, P75], and Min/Max): [Table S1](#). Mild AD phenotype across genotype groups defined by *BCHE-K* allele frequency. [Table S2](#). Mild AD phenotype across genotype groups defined by *APOE4* allele frequency and for *APOE4* homozygotes by the presence of *BCHE-K* alleles. [Table S3](#). Mild AD phenotype across genotype groups defined by *APOE4* and *BCHE-K* carrier status.

[Figure S1](#). Correlations in the overall population and in *APOE4* and *BCHE-K* subgroups of Ng versus YKL-40.

[Ethics committees approving clinical study.](#)

[Acknowledgements](#)

We thank the participants and their companions who participated in the study; the sites, and study team from Ionis for executing the study; Michael Moore (Moore Editing, San Diego, CA, USA), who copyedited and styled the manuscript per journal requirements.

[Author contributions](#)

RML was responsible for study design, statistical analysis plan design, and data interpretation, and wrote the initial draft of the manuscript. TD-S critically reviewed, styled, and gave input into the manuscript. CJ oversaw data collection, data analysis,

and review of the manuscript. DL and QY advised on statistical analysis plan, performed data analysis, data interpretation, and critical review of the manuscript. KM performed clinical operations and data collection. ALE and DLG designed and conducted biomarker analyses and performed data interpretation and critical review of the manuscript. CJM was the lead investigator and performed data collection, data interpretation, participant recruitment, and critical review of the manuscript. All authors reviewed and provided feedback on the manuscript. The authors had full editorial control of the manuscript and provided their final approval of all content.

Funding

The study from which these baseline results were obtained was funded by Biogen and designed and executed by Ionis.

Availability of data and materials

The baseline data that support the findings of this investigation are available in the supplementary materials (Figure S1; Tables S1-S3) and additional data and materials are available upon request.

Declarations

Ethics approval and consent to participate

The trial (NCT03186989) was conducted in accordance with Good Clinical Practice Guidelines of the International Council for Harmonisation, and according to the ethical principles outlined in the Declaration of Helsinki.

Patients provided written, informed consent at the time of recruitment. The study was approved by the institutional review board or independent ethics committee at each investigational site; see supplementary materials (Additional File 2).

Consent for publication

Not applicable.

Competing interests

RML, CJ, DL, QY, KM: Employees of, and holders of stock/stock options in, Ionis. TDS: No conflicts of interest. ALE, DLG: Employees of, and holders of stock/stock options in, Biogen. CJM: Supported by the NIHR Biomedical Research Centre at UCLH; received honoraria for patient and clinician educational activities related to AD from Biogen, Lilly, and Peerview; received institutional consulting/advisory board fees from Biogen, Roche, Eli Lilly, Prevail, Alnylam, Alector, Eisai, WAVE, and Ionis; served as a site-investigator for several clinical trials sponsored by Ionis and Biogen.

Author details

¹Ionis Pharmaceuticals, Carlsbad, CA, USA; ²Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatric, Stockholm, Sweden; ³Biogen, Cambridge, MA, USA; ⁴Dementia Research Centre, Institute of Neurology, London, UK.

Corresponding author

Roger M. Lane, MD, MPH, Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA (rlane@ionisph.com)

References

1. Mesulam MM. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. *The Journal of comparative neurology*. 2013;521(18):4124-44.
2. Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. *Annals of neurology*. 2004;55(6):815-28.
3. Mufson EJ, Ginsberg SD, Ikonovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. *J Chem Neuroanat*. 2003;26(4):233-42.
4. Ballinger EC, Ananth M, Talmage DA, Role LW. Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. *Neuron*. 2016;91(6):1199-218.
5. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain : a journal of neurology*. 2018;141(7):1917-33.
6. Benfante R, Di Lascio S, Cardani S, Fornasari D. Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders. *Aging Clin Exp Res*. 2021;33(4):823-34.
7. Yin Z, Rosenzweig N, Kleemann KL, Zhang X, Brandão W, Margeta MA, et al. APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints. *Nat Immunol*. 2023;24(11):1839-53.
8. Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and tau propagate jointly across Braak stages. *Nature medicine*. 2021;27(9):1592-9.
9. Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, et al. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease. *Nature medicine*. 2023.
10. Kang SS, Ebbert MTW, Baker KE, Cook C, Wang X, Sens JP, et al. Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. *J Exp Med*. 2018;215(9):2235-45.
11. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2006;26(19):4985-94.
12. Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. *Nat Commun*. 2020;11(1):667.
13. Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, et al. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. *Neurobiology of aging*. 2013;34(1):1-12.
14. Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, et al. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. *Neurology*. 2021;97(18):e1823-e34.
15. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. *Nature reviews Neuroscience*. 2003;4(2):131-8.
16. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum*. 2006;9(1):101-24.
17. Vijayaraghavan S, Karami A, Aeinband S, Behbahani H, Grandien A, Nilsson B, et al. Regulated Extracellular Choline Acetyltransferase Activity- The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway. *PloS one*. 2013;8(6):e65936.
18. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. *The Journal of comparative neurology*. 1998;393(3):374-90.

19. Darvesh S, Hopkins DA. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. *The Journal of comparative neurology*. 2003;463(1):25-43.
20. Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, et al. The apolipoprotein E epsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. *Neurobiology of aging*. 2011;32(7):1236-48.
21. Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, et al. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. *Neurobiology of aging*. 2011;32(12):2320 e15-32.
22. Kumar R, Nordberg A, Darreh-Shori T. Amyloid- β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BA β ACs. *Brain : a journal of neurology*. 2016;139(Pt 1):174-92.
23. Teitsdottir UD, Darreh-Shori T, Lund SH, Jonsdottir MK, Snaedal J, Petersen PH. Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects. *Frontiers in aging neuroscience*. 2022;14:876019.
24. Darreh-Shori T, Vijayaraghavan S, Aeinehband S, Piehl F, Lindblom RP, Nilsson B, et al. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. *Neurobiology of aging*. 2013;34(11):2465-81.
25. Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. *J Lipid Res*. 2005;46(5):949-68.
26. Chuang YF, Varma V, An Y, Tanaka T, Davatzikos C, Resnick SM, et al. Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer's Disease in a Prospective Cohort Study. *Journal of Alzheimer's disease : JAD*. 2020;75(2):417-27.
27. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. *Pharmacogenetics and genomics*. 2008;18(4):289-98.
28. Vijayaraghavan S, Maetzler W, Reimold M, Lithner CU, Liepelt-Scarfone I, Berg D, et al. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2014;10(5):530-40.e1.
29. Darreh-Shori T, Siawesh M, Mousavi M, Andreasen N, Nordberg A. Apolipoprotein epsilon4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2012;28(2):443-58.
30. De Beaumont L, Pelleieux S, Lamarre-Th eroux L, Dea D, Poirier J. Butyrylcholinesterase K and Apolipoprotein E- ϵ 4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. *Journal of Alzheimer's disease : JAD*. 2016;54(3):913-22.
31. Gabriel AJ, Almeida MR, Ribeiro MH, Carneiro D, Val erio D, Pinheiro AC, et al. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2018;61(3):1097-105.
32. Lane RM, He Y. Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias. *Medical hypotheses*. 2009;73(2):230-50.
33. Lane RM, Darreh-Shori T. Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value. *Journal of Alzheimer's disease : JAD*. 2015;44(4):1039-62.
34. Mummery CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, et al. Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. *Nature medicine*. 2023.

35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* 1975;12(3):189-98.
36. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. *Neurology.* 1997;48(6):1508-10.
37. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association.* 2011;7(3):270-9.
38. Wang X, Ghayoor A, Novicki A, Holmes S, Seibyl J, Hesterman J. [P4–266]: APPLICATION OF A MULTI-ATLAS SEGMENTATION TOOL TO HIPPOCAMPUS, VENTRICLE AND WHOLE BRAIN SEGMENTATION. *Alzheimer's & Dementia.* 2017;13(7S_Part_28):P1385-P6.
39. Connolly K, Lehoux M, O'Rourke R, Assetta B, Erdemir GA, Elias JA, et al. Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association.* 2022.
40. Graffelman J. Exploring diallelic genetic markers: the HardyWeinberg package. *Journal of Statistical Software.* 2015;64:1-23.
41. Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, et al. Astrocyte biomarker signatures of amyloid- β and tau pathologies in Alzheimer's disease. *Molecular psychiatry.* 2022;27(11):4781-9.
42. Bellou E, Baker E, Leonenko G, Bracher-Smith M, Daunt P, Menzies G, et al. Age-dependent effect of APOE and polygenic component on Alzheimer's disease. *Neurobiology of aging.* 2020;93:69-77.
43. Whitwell JL, Tosakulwong N, Weigand SD, Graff-Radford J, Ertekin-Taner N, Machulda MM, et al. Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. 2021;108:90-8.
44. Schindler S, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, et al. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. *Neurology.* 2021.
45. Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J, Jr., Leung BP, Rezai-Zadeh K, et al. I110 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. *Neuron.* 2015;85(3):534-48.
46. Jain N, Lewis CA, Ulrich JD, Holtzman DM. Chronic TREM2 activation exacerbates Abeta-associated tau seeding and spreading. *J Exp Med.* 2023;220(1).
47. Liu CC, Wang N, Chen Y, Inoue Y, Shue F, Ren Y, et al. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease. *Nat Immunol.* 2023;24(11):1854-66.
48. Hu Y, Fryatt GL, Ghorbani M, Obst J, Menassa DA, Martin-Estebane M, et al. Replicative senescence dictates the emergence of disease-associated microglia and contributes to A β pathology. *Cell reports.* 2021;35(10):109228.
49. Li X, Zhang J, Li D, He C, He K, Xue T, et al. Astrocytic ApoE reprograms neuronal cholesterol metabolism and histone-acetylation-mediated memory. *Neuron.* 2021;109(6):957-70 e8.
50. Jankowska-Kulawy A, Klimaszewska-Łata J, Gul-Hinc S, Ronowska A, Szutowicz A. Metabolic and Cellular Compartments of Acetyl-CoA in the Healthy and Diseased Brain. *Int J Mol Sci.* 2022;23(17).
51. Yu MC, Chuang YF, Wu SC, Ho CF, Liu YC, Chou CJ. White matter hyperintensities in cholinergic pathways are associated with dementia severity in e4 carriers but not in non-carriers. *Frontiers in neurology.* 2023;14:1100322.
52. Hu L, Wong TP, Cote SL, Bell KF, Cuello AC. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice. *Neuroscience.* 2003;121(2):421-32.
53. Bell KF, Claudio Cuello A. Altered synaptic function in Alzheimer's disease. *European journal of pharmacology.* 2006;545(1):11-21.

54. Baidya AT, Kumar A, Kumar R, Darreh-Shori T. Allosteric Binding Sites of A β Peptides on the Acetylcholine Synthesizing Enzyme ChAT as Deduced by In Silico Molecular Modeling. *Int J Mol Sci*. 2022;23(11).
55. Baker-Nigh A, Vahedi S, Davis EG, Weintraub S, Bigio EH, Klein WL, et al. Neuronal amyloid- β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease. *Brain : a journal of neurology*. 2015;138(Pt 6):1722-37.
56. Norvin D, Kim G, Baker-Nigh A, Geula C. Accumulation and age-related elevation of amyloid- β within basal forebrain cholinergic neurons in the rhesus monkey. *Neuroscience*. 2015;298:102-11.
57. Roberts JP, Stokoe SA, Sathler MF, Nichols RA, Kim S. Selective coactivation of $\alpha 7$ - and $\alpha 4\beta 2$ -nicotinic acetylcholine receptors reverses beta-amyloid-induced synaptic dysfunction. *The Journal of biological chemistry*. 2021;296:100402.
58. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. *Experimental neurology*. 2005;192(1):215-25.
59. Hernandez CM, Kaye R, Zheng H, Sweatt JD, Dineley KT. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2010;30(7):2442-53.
60. Suarez-Calvet M, Morenas-Rodriguez E, Kleinberger G, Schlepckow K, Araque Caballero MA, Franzmeier N, et al. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology. *Molecular neurodegeneration*. 2019;14(1):1.
61. Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2013;27(1):187-98.
62. Yin Z, Herron S, Silveira S, Kleemann K, Gauthier C, Mallah D, et al. Identification of a protective microglial state mediated by miR-155 and interferon- γ signaling in a mouse model of Alzheimer's disease. *Nature neuroscience*. 2023.
63. Aloï MS, Prater KE, Sánchez REA, Beck A, Pathan JL, Davidson S, et al. Microglia specific deletion of miR-155 in Alzheimer's disease mouse models reduces amyloid- β pathology but causes hyperexcitability and seizures. *Journal of neuroinflammation*. 2023;20(1):60.
64. Chung WS, Verghese PB, Chakraborty C, Joung J, Hyman BT, Ulrich JD, et al. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(36):10186-91.
65. Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. *Neuron*. 2016;91(2):328-40.
66. Yang Y, Cudaback E, Jorstad NL, Hemingway JF, Hagan CE, Melief EJ, et al. APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease. *The American journal of pathology*. 2013;183(3):905-17.
67. Stephen TL, Brenningstall B, Suresh S, McGill CJ, Pike CJ. APOE genotype and biological sex regulate astroglial interactions with amyloid plaques in Alzheimer's disease mice. *Journal of neuroinflammation*. 2022;19(1):286.
68. Darreh-Shori T, Siawesh M, Mousavi M, Andreasen N, Nordberg A. Apolipoprotein $\epsilon 4$ modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2012;28(2):443-58.
69. Choi I, Wang M, Yoo S, Xu P, Seegobin SP, Li X, et al. Autophagy enables microglia to engage amyloid plaques and prevents microglial senescence. *Nat Cell Biol*. 2023.

70. Lananna BV, McKee CA, King MW, Del-Aguila JL, Dimitry JM, Farias FHG, et al. Chi3I1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis. *Science translational medicine*. 2020;12(574).
71. Bigler ED, Lowry CM, Anderson CV, Johnson SC, Terry J, Steed MJ, et al. Dementia, quantitative neuroimaging, and apolipoprotein E genotype. 2000;21(10):1857-68.
72. Yasuda M, Mori E, Kitagaki H, Yamashita H, Hirono N, Shimada K, et al. Apolipoprotein E ϵ 4 allele and whole brain atrophy in late-onset Alzheimer's disease. 1998;155(6):779-84.
73. Jack Jr CR, Petersen RC, Xu YC, O'Brien PC, Waring SC, Tangalos EG, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. 1998;43(3):303-10.
74. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science (New York, NY)*. 1992;256(5054):184-5.
75. Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. *JAMA neurology*. 2022;79(10):1015-24.
76. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. *The New England journal of medicine*. 2022.
77. Ossenkoppele R, Binette AP, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline? 2022:2022.05.23.22275241.
78. Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jögi J, et al. Greater tau load and reduced cortical thickness in APOE ϵ 4-negative Alzheimer's disease: a cohort study. *Alzheimer's research & therapy*. 2018;10(1):77.
79. Susanto TA, Pua EP, Zhou J. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e. *Journal of Alzheimer's disease : JAD*. 2015;45(1):253-68.
80. Ferrari-Souza JP, Lussier FZ, Leffa DT, Therriault J, Tissot C, Bellaver B, et al. APOE ϵ 4 associates with microglial activation independently of A β plaques and tau tangles. *Sci Adv*. 2023;9(14):eade1474.
81. Schmitz TW, Nathan Spreng R. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. *Nat Commun*. 2016;7:13249.
82. Fernandez-Cabello S, Kronbichler M, Van Dijk KRA, Goodman JA, Spreng RN, Schmitz TW, et al. Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration. *Brain : a journal of neurology*. 2020;143(3):993-1009.
83. Schmitz TW, Soreq H, Poirier J, Spreng RN. Longitudinal Basal Forebrain Degeneration Interacts with TREM2/C3 Biomarkers of Inflammation in Presymptomatic Alzheimer's Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2020;40(9):1931-42.
84. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(47):20057-62.
85. Puzzo D, Argyrousi EK, Staniszewski A, Zhang H, Calcagno E, Zuccarello E, et al. Tau is not necessary for amyloid- β -induced synaptic and memory impairments. *The Journal of clinical investigation*. 2020;130(9):4831-44.
86. Conrado DJ, Denney WS, Chen D, Ito K. An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM. *J Pharmacokinet Pharmacodyn*. 2014;41(6):581-98.
87. Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2019;15(7):888-98.

88. Geula C, Dunlop SR, Ayala I, Kawles AS, Flanagan ME, Gefen T, et al. Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. *Journal of neurochemistry*. 2021;158(6):1394-411.
89. Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. *EMBO Mol Med*. 2016;8(9):992-1004.
90. Wendimu MY, Hooks SB. Microglia Phenotypes in Aging and Neurodegenerative Diseases. *Cells*. 2022;11(13).
91. Salvadó G, Ossenkoppele R, Ashton NJ, Beach TG, Serrano GE, Reiman EM, et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. *EMBO Mol Med*. 2023;15(5):e17123.
92. Tcw J, Qian L, Pipalia NH, Chao MJ, Liang SA, Shi Y, et al. Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. *Cell*. 2022;185(13):2213-33 e25.
93. La Du BN, Bartels CF, Nogueira CP, Hajra A, Lightstone H, Van der Spek A, et al. Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. *Clin Biochem*. 1990;23(5):423-31.
94. Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L, et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. *Molecular psychiatry*. 2014;19(3):351-7.